Wednesday, 29 September 2010

Carbogen-Amcis will work with EirGen Pharma to manufacture highly potent active ingredients and solid oral-dose products for the treatment of cancer


UKTI seeks companies for UK pavilion at ChemSpec Middle East

UK Trade & Investment is seeking UK-based companies offering UK origin (or high UK added value) products and services within the fine and speciality chemical industry with the objective of meeting a Middle Eastern client base at ChemSpec Middle East on 29-30 November 2010.
Chemicals NorthWest

OctoPlus will perform formulation development a global pharmaceutical company's product candidate


Lonza confirms plans to invest in India

Previous announcement

The Hindu Business Line

DSM and Crucell launch newco

DSM and Crucell have launched Percivia LLC, a joint venture focused on the development of "biobetter" proteins and monoclonal antibodies using their PER.C6 technology. The company, which will be based in Cambridge, MA, will also license the PER.C6 human cell line for production of third party monoclonal antibodies and other proteins.

Tuesday, 28 September 2010

OctoPlus will provide clinical manufacturing for a French biopharmaceutical company


KemFine UK sold to Aurelius

KemFine has sold its UK facility in Grangemouth to Aurelius. Financial details have not been disclosed and the deal is expected to close later this year. In February, Aurelius acquired Isochem from SNPE.
The Scotsman

Wednesday, 15 September 2010

Grace to acquire Synthetech

WR Grace is to acquire Synthetech for $19.2 million, less Synthetech’s unpaid debt and transaction costs at closing, and subject to a minimum cash balance of $600,000. The acquisition will expand Grace's pharmaceutical offering by adding expertise in chiral and peptide intermediate synthesis in addition to capacity for the manufacture of specialty single-site and polypropylene catalysts used to produce plastics.
Baltimore Sun

Thursday, 9 September 2010

Diosynth RTP will manufacture the API for Nabi Biopharmaceuticals' NicVAX anti-smoking vaccine

Nabi Biopharmaceuticals

Lonza signs manufacturing deal with GSK

GlaxoSmithKline has selected Lonza to produce early stage monoclonal antibodies from its biopharmaceutical pipeline. Initially Lonza will manufacture clinical trial batches of five compounds currently in Phase I and II. In addition GSK will also have flexible access to Lonza's capabilities for future demand dependent upon progression of molecules through late stage development and commercial launch.

Socma welcomes R&D Tax Credit decision

Socma has welcomed the decision by US President Barack Obama to to expand and simplify the R&E Tax Credit and to make it permanent to help encourage future productivity and growth. Socma has advocated for this for a numb roof years, said Socma President and CEO Lawrence Sloan welcoming the plan.